LiuMJYangJYYanZHHuSLiJQXuZXet al
Table 5: Changes from Week 26 Baseline to Week 52 in IGF-1, IGFBP-3, Weight, and Waist Circumference by Treatment Group (Intent-To-Treat Population with Last Observation Carried Forward) Patients treated with a 2 mg dose of EGRIFTA (1 mg/formulation) for 52 weeks (T-T group) showed no change between Weeks 26 and 52 in mean trunk fat (increase of 0.1 kg in Study 1 and decrease of 0.5 kg in Study 2, respectively, compared with an increase of 1.4 kg in patients in the T-P group in Study 1 and an increase of 1.09 kg in Study 2, respectively) nor was there a change from Week 26 baseline in mean lean body mass (decrease of 0.1 kg in Study 1 and increase of 0.1 kg in Study 2, respectively, compared with a decrease of 1.8 kg in patients in the T-P group in Study 1 and a decrease of 1.7 kg in Study 2, respectively)
10.3390/nu14142913 236
The operational challenge is that the FDA-approved HRT formulary doesnt cover every patientand the patients it doesnt cover are arriving in numbers that compounding pharmacies were not built to handle through phone calls and fax machines
How is this different from injection or capsules
Carter BZ, Zhang N, Coombes KR, Mak DH, Qiu Y, Thomas DA, Ravandi F, Kantarjian H, Andreeff M, Kornblau SM
